Fusion between nonsynchronized cells leads to the formation of heterokarya which transiently activate Cyclin-dependent kinase 1 (Cdk1)/cyclin B1 and enter the prophase of the cell cycle, where they arrest due to a loss of Cdk1/cyclin B1 activity, activate p53, disorganize centrosomes, and undergo apoptosis. Here, we show that the down regulation of Cdk1/cyclin B is secondary to the activation of the DNA structure checkpoint kinase Chk2. Thus, syncytia generated by the fusion of asynchronous HeLa cells contain elevated levels of active Chk2 but not Chk1. Chk2 bearing the activating phosphorylation on threonine-68 accumulates in BRCA1 nuclear bodies when the cells arrest at the G2/M boundary. Inhibition of Chk2 by transfection of a dominant-negative Chk2 mutant or a chemical inhibitor, debromohymenialdesine, stabilizes centrosomes, maintains high cyclin B1 levels, and allows for a prolonged activation of Cdk1. Under these conditions, multinuclear HeLa syncytia do not arrest at the G2/ M boundary and rather enter mitotis and subsequently die during the metaphase of the cell cycle. This mitotic catastrophe is associated with the activation of the proapoptotic caspase-3. Inhibition of caspases allows the cells to go beyond the metaphase arrest, indicating that apoptosis is responsible for cell death by mitotic catastrophe. In another, completely different model of mitotic catastrophe, namely 14.3.3r-deficient HCT116 colon carcinoma cells treated with doxorubicin, Chk2 activation was also found to be deficient as compared to 14.3.3r-sufficient controls. Inhibition of Chk2 again facilitated the induction of mitotic catastrophe in HCT116 wild-type cells. In conclusion, a conflict in cell cycle progression or DNA damage can lead to mitotic catastrophe, provided that the checkpoint kinase Chk2 is inhibited. Inhibition of Chk2 thus can sensitize proliferating cells to chemotherapy-induced apoptosis.
Introduction
Mitotic catastrophe is a poorly defined type of death occurring during mitosis or resulting from failed mitosis (Lock and Stribinskiene, 1996; Roninson et al., 2001 ), related to a premature activation of cyclin-dependent kinase-1 (Cdk1). The perfect regulation of the spatiotemporal pattern of Cdk1 activity is pivotal for the normal entry into mitosis and is subjected to multiple control steps. Thus, the so-called 'DNA structure checkpoint' (which is activated by incomplete DNA replication or by DNA damage such as strand breaks) prevents the activation of the Cdk1/cyclin B complex (the 'mitosis-promoting factor') required for the entry into mitosis. This can be achieved by activating the socalled checkpoint kinases (Chk1, Chk2), which suppress the activation of the Cdk1/cyclin B complex (Nigg, 2001; Smits and Medema, 2001; Melo and Toczyski, 2002) . The fusion of mitotic cells with interphase cells in S or G2 can result into mitotic catastrophe, presumably due to the Cdk1/cyclin B1-driven premature induction of mitosis before the completion of S or G2 (Mackey et al., 1996; Roninson et al., 2001) . Ectopic overexpression of cyclin B plus Cdk1 can result in premature chromatin condensation and mitotic catastrophe (Heald et al., 1993; Jin et al., 1998) . Similarly, the knock-out of the cytoplasmic binding protein 14-3-3s has been reported to favor the translocation of the Cdk1/cyclin B1 complex to the nucleus, thereby preventing the G2 arrest that is normally induced by DNA damage. This failed G2 arrest culminates in mitotic catastrophe (Chan et al., 1999) .
DNA damage such as double-strand breaks is perceived by sensors (which include RAD1, RAD9, RAD17, and HUS7) and then relays to kinases such as ATM and ATR, which phosphorylate and activate yet another kinase, such as the checkpoint kinase-2 (Chk2), which halts the cell cycle. In mammals, Chk2 probably functions as effector through phosphorylation of additional key substrates such as the transcription factor p53 (Chehab et al., 2000; Sheih et al., 2000) , the cell-cycle regulating phophatases Cdc25A (Falck et al., 2000) and Cdc25C (Peng et al., 1997) , Mdm2 (Sheih et al., 2000) , BRCA1 (Lee et al., 2000) and PML (Yang et al., 2002) , and perhaps Abl1, Bub1R, Bub1, Bub3, Psk-H1, Smc3, Plk1, Cdc25B, Dcamkl1, Mre11, Pms1, and Xrcc9 (Seo et al., 2003) . In addition, Chk2 phosphorylates the transcription factor E2F1 on serine 364, thereby activating the transcriptional upregulation of the proapoptotic proteins Apaf-1 and p73 (Stevens et al., 2003) . Chk2 also colocalizes and interacts with polo-like kinase 1 (Plk-1), in centrosomes and the midbody in human cells (Tsvetkov et al., 2003) , and results obtained in Drosophila suggest that Chk2 couples centrosome function and spindle assembly to genomic integrity via Plk-1 (Takada et al., 2003; Xu and Du, 2003) . In accord, with these pleiotropic effects, Chk2 can have an apoptosis-sensitizing effect and can arrest the cell cycle at different stages. Indeed, activation of Chk2 can inhibit Cdk1 at several levels (Nigg, 2001 ).
We have recently described a model of cell fusioninduced cell death in which the transient activation of Cdk1/cyclin B is required for later apoptosis to occur (Ferri et al., 2000a; Castedo et al., 2002a; Castedo et al., 2002b) . In this system, the fusogenic interaction between the HIV-1 envelope and CD4 results into the formation of syncytia, which transiently activate Cdk1/cyclin B and enter the early prophase of mitosis (as defined by dismantling of the nuclear envelope) during which cyclin B is rapidly downregulated, thereby preventing further progression into mitosis (Castedo et al., 2002b) . At this stage, cells activate p53 and transcribe p53 target genes including Bax, which induces mitochondrial membrane permeabilization (MMP) with subsequent cytochrome c-mediated caspase activation (Ferri et al., 2000a; Castedo et al., 2001; Perfettini et al., 2004; Roumier et al., 2003) . The cells thus undergo apoptosis before mitosis. Here, we addressed the question as to whether maintenance of the activity of Cdk1/cyclin B would induce mitotic catastrophe. We show that inhibition of Chk2 allows for a protracted activation of the Cdk1/ cyclin B complex with subsequent progression to the metaphase and mitotic catastrophe. The link between Chk2 and mitotic catastrophe has been confirmed in a model of DNA-damage-induced cell death.
Results and discussion
Activation of Chk2 in a model of fusion-induced prophaseassociated apoptosis Two HeLa cell lines engineered to stably express the HIV-1 envelope (Env) or the Env receptor CD4, form syncytia upon coculture. Such syncytia die after a latency phase, during the prophase of the cell cycle when an mTOR-mediated activating phosphorylation of the p53 molecule (on serine 15: p53S15P) occurs and proapoptotic p53 target genes are expressed (Ferri et al., 2000a; Castedo et al., 2001 Castedo et al., , 2002b . Different from single cells, syncytia manifest also an activating phosphorylation of the cell cycle checkpoint kinase-2 (Chk2) on threonine 68 (Chk2T68P) (McGowan, 2002) . In contrast, the checkpoint kinase-1 (Chk1) was not activated in syncytia, as indicated by the absence of the activating phosphorylation of Chk-1 on serine 345, a phosphorylation pattern that was readily observed in hydroxyurea-treated cells (Figure 1a ). Chk2T68P exhibited a speckled, predominantly nuclear staining pattern, and colocalized with BRCA-1 (but not with p53S15P, not shown) in nuclear bodies, as this would have to be expected from activation of the DNA structure checkpoint (Smits and Medema, 2001; Melo and Toczyski, 2002) . (Figure 1b) . Freshly formed prekaryogamic (pre-KG) syncytia were still negative for Chk2T68P. However, syncytial prophases (whose morphological correlate is nuclear fusion, KG, due to dismantling of the nuclear envelope) (Castedo et al., 2001) were positive for Chk2T68P (Figure 2a, c) at the same time when they lost the expression of cyclin B (Figure 2b ). Kinetic studies confirmed that the Chk2T68P became detectable at the same time when p53S15P emerged, well before nuclear apoptosis occurred ( Figure 2d ). In conclusion, it appears that Chk2 is activated in a model of fusion-induced prophaseassociated apoptosis. þ in BRCA1 nuclear bodies. Cells were stained for the detection of Chk2T68P and BRCA1, followed confocal immunofluorescence microscopy to visualize colocalization (yellow) of the two proteins. This partial overlap in the immunolocalization of Chk2 and BRCA1 was representative of the majority (490%) of the cells analysed mutant (van den Heuvel and Harlow, 1993) ( Figure  3c ,d), a manipulation that blocks the Cdk1-mediated dismantling of nuclear envelopes (as manifested by KG), largely suppressed the Chk2T68P phosphorylation occurring in syncytia. In contrast, inhibition of mTOR (with rapamycin), p53 (with pifithrin-a) or caspases (with Z-VAD.fmk) had no effect on the Chk2 activation, yet did reduce syncytial apoptosis, as an internal control of their efficacy (Figure 3a ). In conclusion, it appears that fusion among nonsynchronized cells results into Cdk1-dependent entry into early mitosis, thereby provoking a conflict in cell cycle which activates Chk2. Chk2 activation occurs, however, independently from the activation of p53 and caspases and thus is not a consequence of apoptosis.
Chk2 inhibition reverses the fusion-induced block in the prophase
Transfection with a DN mutant of Chk2 (Matsuoka et al., 1998; Chehab et al., 2000) abolished the block in the prophase (KG) ensuing syncytium formation and thus allowed the heterokarya to proceed further into mitosis. DN Chk2 had no inhibitory effect on the p53S15P phosphorylation (Figure 4a,b) . A phenocopy of this genetic manipulation could be obtained by pharmacological inhibition of Chk2 using debromohymenialdisine (DBH) (Barrios Sosa et al., 2000; Curman et al., 2001) , which acts in a dose-dependent manner to increase the frequency of syncytial mitosis (Figure 4c) . To address the specificity of this effect, we took advantage of several chemical derivatives of DBH. Mitogenic effects were only observed for DBH as well as for its dibromo derivative. However, no such effect was observed when hymenial moiety of DBH was modified (Figure 4d ) and the inhibition of check point kinase is lost (Barrios Sosa et al., 2000; Curman et al., 2001 ). In conclusion, genetic or chemical inhibition of Chk2 can abrogate the fusion-induced block in the prophase.
Chk2 inhibition postpones the fusion-induced arrest by stabilizing centrosomes and the activity of Cdk1
Chk2 has been reported to regulate the integrity of centrosomes (Takada et al., 2003) . Accordingly, we found activated Chk2 (Chk2T68P) and g-tubulin, a centrosome component, to colocalize in freshly formed syncytia (Figure 5a ). This colocalization was lost in karyogamic cells, when Chk2T68P enriched in nuclear bodies while centrosomes disintegrated (Figure 5b ). Inhibition of Chk2 by DBH prevented the disintegration of centrosomes. Upon DBH treatment, g-tubulin and Chk2T68P continued to co-localize in mitotic cells (Figure 5c ). Our previous studies indicated that the arrest of syncytia in the prophase of cell cycle was due to a transient increase in Cdk1/cyclin B activity, followed by its sudden decline (Castedo et al., 2002b) . While only a minority of untreated control syncytia stained positively for cyclin B, this percentage rose to 480% after DBH treatment (Figure 6a) . Immunoprecipitation of the Cdk1/cyclin B complex confirmed a higher Cdk1 activity (measured on histone H1) in syncytia treated The asterisk indicates significant mitogenic effect of DN Chk2. Similarly, the frequency of p53S15P þ cells was measured. (c) Mitogenic effect of debromohymenialdisine (DBH) on syncytia. HeLa Env/CD4 cocultures were exposed to the indicated dose of DBH (added from the beginning of coculture) and the frequency of p53S15P þ and mitotic syncytia was determined by Hoechst 33342/-tubulin staining. (d) Specificity of the effects of DBH. Syncytia arising from the coculture of the two fusogenic cell lines were generated in the absence (control) or presence of the indicated compounds. The maximum dose that gave no toxic effect (as defined as 45% surmortality) is listed and the percentage of mitoses induced by the compound at this maximum dose was determined as in (c) with DBH as compared to untreated syncytia ( Figure 6b ). In synthesis, it appears that Chk2 inhibition maintains centrosome integrity, sustains Cdk1 activity, and hence promotes mitosis.
Chk2 inhibition induces mitotic catastrophe with signs of apoptosis
Intrigued by the possibility that DBH-treated polyploid cells would divide (which, on theoretical grounds, could yield aneuploid cells due to asymmetric division) (Nigg, 2001) , we investigated the fate of mitotic syncytia. Metaphases of DBH-treated syncytia were only exceptionally (o1%) followed by nuclear division and mostly resulted in a more pronounced, irregular chromatin condensation (Figure 7a,b) followed by cell death. Cell death was accompanied by the proteolytic maturation of caspase-3, one of the principal apoptotic effectors (Figure 7b ). In the presence of the pan-caspase inhibitor Z-VAD.fmk, which efficiently blocks the activation of caspase-3, this metaphase-associated death was suppressed, and the cells proceeded to anaphase, telophase, and cytokinesis (Figure 7a,b) . This observation suggests that apoptosis accounts for the catastrophic abortion of DBH-induced metaphases.
Mitotic catastrophe induced by DNA damage relies on Chk2 inhibition
One of the few studies that explored mitotic catastrophe in molecular terms has been performed on HCT116 colon carcinoma cells treated with the DNA-damaging drug doxorubicin (Chan et al., 1999) . In this model, the knockout of the cell cycle regulator 14-3-3s facilitates the translocation of active Cdk1/cyclin B complexes into the nucleus, prevents G2 arrest, and thus triggers mitotic catastrophe (Chan et al., 1999) . Treatment of such doxorubicin-stimulated 14-3-3s À/À cells with Z-VAD.fmk strongly reduced the frequency of hypoploid (apoptotic) cells (Figure 8a ), suggesting that mitotic catastrophe might be linked to a similar sequence of events as that found in the syncytial model. Accordingly, doxorubicin strongly induced the activating phosphorylation of Chk2 (Chk2T68P) in 14-3-3s þ / þ HCT116 control cells, but exerted a much less pronounced effect on the 14-3-3s À/À clone (Figure 8b,c) . This suggested that the 14-3-3s À/À mutation is permissive for mitotic catastrophe through a partial blockade of Chk2 activation. This hypothesis was confirmed by transfection with DN Chk2 or DBH treatment. Inhibition of Chk2 by either of these procedures facilitated the doxorubicin-induced mitotic catastrophe of control cells, meaning that it reduced the G2 blockade and concomitantly increased the frequency of apoptotic cells (Figure 8d ). In contrast, DN Chk2 (or DBH) only had a minor death-accelerating effect on 14-3-3s À/À cells (Figure 8d ). Altogether, these data confirm the important role of Chk2 as an endogenous repressor of mitotic catastrophe.
Concluding remarks
The results shown in this paper outline a molecular pathway leading to mitotic catastrophe. Chk2, which is activated as a result of a conflict in cell cycle progression -3a) and of GAPDH as a loading control. This experiment has been repeated five times, yielding similar results (Figures 1-3 ) or DNA damage (Figure 8 ) (Nigg, 2001; Lou et al., 2003; Lukas et al., 2003) , normally limits the activation of Cdk1/cyclin B, thereby arresting the cell cycle at the G2/M boundary. When Chk2 activation is reduced (by the knockout of 14-3-3s, Figure 8 ) or Chk2 is inhibited (by transfection with DN Chk2 or by pharmacological inhibition with DBH, Figures 4-7) , Cdk1/cyclin B remains active and the cells enter mitosis. During the metaphase, the cells then die from apoptosis.
Mitotic catastrophe is a clinically important modality of cell death, because DNA damage, for instance induced by g-irradiation, which normally activates the DNA damage checkpoint, fails to do so in cancer cells lacking sensors of DNA damage (e.g. ATM, ATR), adapters (e.g. BRCA1) or effector kinases (e.g. Chk1, Chk2) required for cell-cycle arrest (Melo and Toczyski, 2002) . This may explain why, at least in some cases, tumor cells are particularly sensitive to the induction of mitotic catastrophe. Chemical inhibitors of checkpoint kinases (such as DBH used in this study) might sensitize tumor cells to the induction of mitotic catastrophe (and subsequent apoptosis) (Graves et al., 2000; Curman et al., 2001; Hirose et al., 2001; Hu et al., 2001) . Indeed, inhibition of Chk2 (and Chk1) by 7-hydroxystaurosporine (UCN-01) abrogates the g-radiation-induced G2-M checkpoint and thus enhances g-radiation-induced apoptosis (Yu et al., 2002) . Clinical trials involving a combination of UCN-01 and DNA-damaging agents are underway and have yielded encouraging results for patients with melanoma and refractory anaplastic large-cell lymphoma (Senderowicz, 2003) . However, it is not clear which of the effects of UCN-01 may actually be attributed to the inhibition of Chk2 (rather than that of other kinases), and whether the inhibition of Chk2 will not ultimately increase À/À cells (À/À) were for the indicated period with doxorubicin and the phosphorylation status of Chk2 was determined with the Chk2T68P-specific antibody. (d) Effect of Chk2 inhibition on mitotic catastrophe of colon carcinoma cells. Wild-type HCT116 cells ( þ / þ ) and 14-3-3sÀ/À cells (À/À) were cultured in the absence or in the presence of Doxo and/or DBH for 72 h, followed by determination of the frequency of apoptotic cells. Alternatively, cells were transfected with vector only or with a DN Chk2 mutant 24 h before the addition of Doxo for 72 h. Then the frequency (X7s.e.m., n ¼ 3) of apoptotic cells was determined as in (a) or accelerate genomic instability (Bell et al., 1999; MeijersHeijboe et al., 2002; Vahteristo et al., 2002) , thereby favoring the development of therapy-resistant tumor cells or even secondary cancers. Although attractive, the possibility to inhibit Chk2 (and similar enzymes) for chemosensitization has to be validated by extensive biological and clinical tests.
In summary, it appears that Chk2 negatively regulate mitotic catastrophe, meaning that the inactivation of Chk2 (and of its activating partners) can sensitize to this type of cell death. Irrespective of the possible therapeutic application of this knowledge, the model systems developed in this paper constitute an interesting system for the investigation of the molecular mechanisms governing mitotic catastrophe .
Materials and methods

Cell culture and transfection protocols
HeLa cells stably transfected with the env gene of HIV-1 LAI (HeLa env) and HeLa cells transfected with CD4 (HeLa CD4) were cocultured at a 1 : 1 ratio (Ferri et al., 2000a) in the absence or presence of DBH (standard dose 20 mM), and its derivatives (Barrios Sosa et al., 2000) , and/or Z-VAD.fmk (100 mM) (from Enzyme Systems), roscovitine (1 mM), N9-olomoucine, rapamycin (1 mM, Sigma), cyclic pifithrin-a (10 mM) and/or Z-VAD.fmk (100 mM) or other caspaseinhibitors (from enzyme systems). Derivatives of the HCT116 cell line (parental or 14-3-3s
, generously provided by B Vogelstein) were treated with doxorubicin (200 nM, Sigma). Transfection with pcDNA3.1 vector only, wild type (WT) or DN CDk1 mutant (van den Heuvel and Harlow, 1993), wild-type Chk2 or DN Chk2 (Stevens et al., 2003) or p53 DN plasmids (gift by T. Soussi), were performed with Lipofectamine (InVitroGen) 24 h before coculture of HeLa CD4 and HeLa env cells or 24 h before the addition of Doxo to HCT116 cell lines. In some experiments, transfections were performed in the presence of the pDsRed-mito plasmid (ClonTech), 30% of the quantity of the other plasmid to identify transfected cells.
Immunofluorescence and cytofluorometry
HeLa CD4 cells or HeLa Env cells were labeled with CellTracker t Red (15 mM, 30 min at 371C in complete medium) or CMAC (7-amino-4-chloromethylcoumarin; 15 mM, 30 min in serum-free medium), respectively, and washed extensively before coculture (Ferri et al., 2000b) . Rabbit antisera specific for p53S15P, Chk268P, Cdk1T15P, Casp-3a (Cell Signaling Technology, MA, USA), was used on paraformaldehyde (4% w : v) and picric acid-fixed (0.19% v : v) cells (Daugas et al., 2000; Boya et al., 2003) and revealed with a goat anti-rabbit IgG conjugated to Alexa 568 (red) or Alexa 488 (green) fluorochromes from Molecular Probes. Cells were also stained for the detection of Chk2 (mAb), cyclin B (mAb, BD Transduction Laboratories), BRCA1 (mAb OP92, Oncogene Science), -or g-tubulin (mAb, Sigma), revealed by anti-mouse IgG Alexa conjugates. Cytofluorometric analyses were performed by staining of trypsinized syncytia as above, counterstaining with diaminidophenylindol (DAPI), and gating on cells with a DNA content 44 N on a FACS Vantage (Becton Dickinson) equipped with a 100 mM nozzle and CellQuest software (Roumier et al., 2003) . HCT116 cells were analysed on the FACS using a convention 50 mm nozzle after immunofluorescence staining (after paraformaldehyde fixation) or DAPI staining (after ethanol fixation), and gates were set to identify the MtDsRED-expressing, transfected subpopulation of cells.
Immunoblots, and in vitro kinase assays
Protein samples were prepared from HeLa Env and HeLa CD4 single cells mixed at a 1 : 1 ratio in lysis buffer (0 control) or from HeLa Env/CD4 syncytia obtained after 9, 18 or 36 h of coculture. Aliquots of protein extracts (40 mg) were subjected to immunoblots using antibodies specific for Chk1S345P, Chk2T68P, p53S15P, Casp-3a (Cell Signaling Technology), Chk2, (BD Transduction Laboratories), Cdk1 (Santa Cruz), or glyceraldehyde-3-phosphated dehydrogenase (GAPDH, mAb from Chemicon). The capacity of immunoprecipitated cyclin B/Cdk1 to phosphorylate histone H1 was assessed (Pines and Hunter, 1994) .
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